Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.

Reischer A, Leutbecher A, Hiller B, Perini E, White K, Hernández-Cáceres A, Schele A, Tast B, Rohrbacher L, Winter L, Czogalla B, Mahner S, Flaswinkel H, Leonhardt H, Wyder L, Wichmann C, Maenner D, Trillsch F, Kessler M, Hopfner KP, Fenn NC, Subklewe M

Open source

DOI: 10.1007/s00262-025-04032-0
Published: 2025 May 22
Container: Cancer immunology, immunotherapy : CII
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-025-04032-0,
  title = {Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.},
  author = {Reischer A and Leutbecher A and Hiller B and Perini E and White K and Hernández-Cáceres A and Schele A and Tast B and Rohrbacher L and Winter L and Czogalla B and Mahner S and Flaswinkel H and Leonhardt H and Wyder L and Wichmann C and Maenner D and Trillsch F and Kessler M and Hopfner KP and Fenn NC and Subklewe M},
  year = {2025},
  journal = {Cancer immunology, immunotherapy : CII},
  doi = {10.1007/s00262-025-04032-0},
  url = {https://doi.org/10.1007/s00262-025-04032-0}
}

RIS

TY  - JOUR
TI  - Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.
AU  - Reischer A
AU  - Leutbecher A
AU  - Hiller B
AU  - Perini E
AU  - White K
AU  - Hernández-Cáceres A
AU  - Schele A
AU  - Tast B
AU  - Rohrbacher L
AU  - Winter L
AU  - Czogalla B
AU  - Mahner S
AU  - Flaswinkel H
AU  - Leonhardt H
AU  - Wyder L
AU  - Wichmann C
AU  - Maenner D
AU  - Trillsch F
AU  - Kessler M
AU  - Hopfner KP
AU  - Fenn NC
AU  - Subklewe M
PY  - 2025
JO  - Cancer immunology, immunotherapy : CII
DO  - 10.1007/s00262-025-04032-0
UR  - https://doi.org/10.1007/s00262-025-04032-0
ER  -

APA

A, R., A, L., B, H., E, P., K, W., A, H., A, S., B, T., L, R., L, W., B, C., S, M., H, F., H, L., L, W., C, W., D, M., F, T., M, K., KP, H., NC, F., & M, S. (2025). Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-025-04032-0

Source records

pubmed · retrieved 2026-09-25T00:19:22.609Z